Periprocedural management of rivaroxaban-treated patients

Davide Imberti, Andrea Ambrosoli, Claudio Cimminiello, Christian Compagnone, Andrea Fanelli, Armando Tripodi, Filippo Ottani

Research output: Contribution to journalArticlepeer-review


Introduction: The increasing and widespread use of direct oral anticoagulants (DOACs) demands guidelines and experts' consensus for their rational and safe use, especially in certain situations for which there is no evidence-based consensus, such as the periprocedural setting. Rivaroxaban is an oral factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF) and for treatment and prevention of venous thromboembolism (VTE) in major orthopedic surgery. This article is addressed to all the clinicians involved in the periprocedural approach of patients treated with rivaroxaban, with the aim to give practical recommendations to improve patients' management during and after surgery. Areas covered: This article is based on a consensus of specialists involved in anticoagulant treatment and in periprocedural setting, including experts in thrombosis, cardiologists, internists, clinical pathologists and anesthesiologists. The authors performed a review of the literature and expressed statements based on the results of the review as well as on personal experience. Expert opinion: Rivaroxaban is a safe and effective drug that simplifies management of anticoagulation also in patients undergoing invasive procedures. However, periprocedural management could be challenging and physicians must carefully balance the risk of bleeding and the risk of thrombosis.

Original languageEnglish
Pages (from-to)685-691
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Issue number5
Publication statusPublished - Apr 1 2015


  • Anesthesia
  • Direct oral anticoagulants
  • Periprocedural management
  • Rivaroxaban
  • Surgery

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)


Dive into the research topics of 'Periprocedural management of rivaroxaban-treated patients'. Together they form a unique fingerprint.

Cite this